Progyny (NASDAQ:PGNY) Stock Rating Raised to "Strong-Buy" at Zacks Research

Progyny logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Zacks Research upgraded Progyny from “hold” to “strong-buy.” Analysts’ consensus rating remains “Moderate Buy,” with an average price target of $35.83.
  • Progyny reported quarterly EPS of $0.52, beating estimates of $0.31, while revenue of $341.25 million slightly topped forecasts and rose 8.9% year over year.
  • Company insiders sold a combined 630,072 shares, worth about $22.4 million, over the past 90 days; the reported transactions were made under pre-arranged trading plans.
  • Interested in Progyny? Here are five stocks we like better.

Progyny (NASDAQ:PGNY - Get Free Report) was upgraded by research analysts at Zacks Research from a "hold" rating to a "strong-buy" rating in a research report issued on Wednesday, Zacks reports.

Other research analysts have also recently issued reports about the company. Cantor Fitzgerald lifted their price objective on Progyny from $31.00 to $35.00 and gave the company an "overweight" rating in a report on Thursday, November 5th. Citizens Jmp lifted their price target on shares of Progyny from $33.00 to $38.00 and gave the company a "market outperform" rating in a research note on Thursday, November 5th. Jefferies Financial Group set a $33.00 price target on shares of Progyny in a research report on Tuesday, September 8th. Citigroup reissued a "market outperform" rating on shares of Progyny in a research report on Thursday, November 5th. Finally, Barclays lowered their price objective on shares of Progyny from $34.00 to $30.00 and set an "equal weight" rating for the company in a research report on Wednesday, August 12th. One investment analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating and three have issued a Hold rating to the company. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $35.83.

View Our Latest Stock Analysis on PGNY

Progyny Trading Down 2.0%

PGNY opened at $35.45 on Wednesday. The stock has a market cap of $2.61 billion, a price-to-earnings ratio of 32.52, a PEG ratio of 1.66 and a beta of 0.97. The stock has a fifty day moving average price of $29.24 and a 200 day moving average price of $25.12. Progyny has a 1 year low of $16.10 and a 1 year high of $37.21.

Progyny (NASDAQ:PGNY - Get Free Report) last issued its quarterly earnings data on Wednesday, November 4th. The company reported $0.52 EPS for the quarter, beating analysts' consensus estimates of $0.31 by $0.21. The business had revenue of $341.25 million for the quarter, compared to analyst estimates of $340.76 million. Progyny had a return on equity of 19.82% and a net margin of 6.80%. The firm's revenue for the quarter was up 8.9% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.15 EPS. As a group, sell-side analysts forecast that Progyny will post 1.43 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, CFO Mark Livingston sold 2,139 shares of Progyny stock in a transaction on Wednesday, November 4th. The shares were sold at an average price of $30.00, for a total transaction of $64,170.00. Following the completion of the sale, the chief financial officer directly owned 70,314 shares of the company's stock, valued at approximately $2,109,420. The trade was a 2.95% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Chairman David Schlanger sold 35,392 shares of the business's stock in a transaction on Tuesday, November 10th. The stock was sold at an average price of $35.36, for a total transaction of $1,251,461.12. Following the completion of the sale, the chairman directly owned 238,462 shares of the company's stock, valued at $8,432,016.32. This represents a 12.92% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 630,072 shares of company stock valued at $22,363,084 in the last ninety days. 9.90% of the stock is owned by insiders.

Hedge Funds Weigh In On Progyny

Hedge funds have recently added to or reduced their stakes in the company. Algert Global LLC bought a new stake in Progyny in the 3rd quarter worth approximately $1,340,000. Aristides Capital LLC bought a new stake in Progyny during the 3rd quarter worth approximately $346,000. Goldman Sachs Group Inc. boosted its holdings in Progyny by 23.3% in the 3rd quarter. Goldman Sachs Group Inc. now owns 530,279 shares of the company's stock worth $13,358,000 after buying an additional 100,335 shares during the period. AWM Investment Company Inc. lifted its holdings in Progyny by 6.8% in the 3rd quarter. AWM Investment Company Inc. now owns 235,000 shares of the company's stock worth $5,920,000 after purchasing an additional 15,000 shares in the last quarter. Finally, Kovack Advisors Inc. purchased a new position in Progyny during the third quarter valued at $72,000. 94.93% of the stock is currently owned by hedge funds and other institutional investors.

Progyny Company Profile

(Get Free Report)

Progyny, Inc. provides fertility and family-building benefits to employers and their employees. Its services are designed to help members navigate care options, access fertility specialists and receive support throughout treatment. The company's offerings include coverage for treatments such as in vitro fertilization and egg freezing, along with fertility medications through its pharmacy benefit. Progyny also supports other family-building paths, including adoption and surrogacy, depending on the plan selected by an employer.

Featured Articles

Analyst Recommendations for Progyny (NASDAQ:PGNY)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Progyny Right Now?

Before you consider Progyny, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Progyny wasn't on the list.

While Progyny currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The 7 Hottest IPO Stories of 2026 Cover

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines